AURA

Aura Biosciences, Inc.

7.74

+1.01+15.01%

After Hours: 7.75 +0.01 +0.13%19:41 07/02 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE6.77/6.73

TODAY RANGE6.58-7.75

VOL961.70K

MARKET CAP800.60M

52 WEEK RANGE4.730-9.54

AVG VOL (3M)614.59K

% TURNOVER0.93%

TURNOVER--

P/E (TTM)-4.4424

% RANGE17.24%

EPS(TTM)-1.7423

P/E(FORWARD)-5.2121

P/B4.630

BVPS1.672

DIVIDEND--

P/S--

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP750.11M

SHARES OUTSTANDING103.44M

NEXT EARNINGS--

FREE FLOAT96.91M

LOT SIZE1

EX-DATE--

News

Press Releases

Financial Reports

Profile

NASDAQ·1d ago
Top Biotech Gainers: PPCB Launches Share Buyback, VRXA Partners With ATUM, SLS On Watch
TipRanks·2d ago
3 Under-$10 Stocks With Strong Upside to Watch in July 2026, According to Analysts
PUBT·06/17 20:31
Aura Biosciences announces special shareholder meeting
TipRanks·06/17 02:11
Top Aura Biosciences Executive Quietly Unloads Shares in Notable Insider Move
TipRanks·06/11 22:15
Aura Biosciences Announces Results of 2026 Annual Meeting
PUBT·06/11 20:31
Aura Biosciences shareholders elected directors at annual meeting
TipRanks·06/05 03:30
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks·06/01 12:46
Aura Biosciences completes enrollment in belzupacap sarotalocan trial
Benzinga·06/01 12:14
Aura Biosciences Announces 108 Patients Enrolled In The Phase 3 Trial Evaluating Belzupacap Sarotalocan As A Frontline Treatment For Patients With Early Choroidal Melanoma; Topline Data Expected In H2 2027
PUBT·06/01 12:01
Aura Biosciences completes enrollment in Phase 3 CoMpass trial of bel-sar in early choroidal melanoma
Reuters·06/01 12:00
AURA BIOSCIENCES ANNOUNCES ENROLLMENT COMPLETION IN PHASE 3 COMPASS TRIAL OF BEL-SAR IN EARLY CHOROIDAL MELANOMA
NASDAQ·05/27 20:04
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
TipRanks·05/26 17:40
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Century Therapeutics (IPSC) and Belite Bio, Inc. ADR (BLTE)
PUBT·05/19 20:51
Aura Biosciences grants new CEO 2.17 million stock options at $7.39 share price
Reuters·05/19 20:50
AURA BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Same Industry

Name/Symbol

Change%

Price

AURA

Regeneron Pharmaceuticals

REGN

+0.05%

633.19

GridAI Tech

GRDX

+1.85%

4.410

BIONTECH

BNTX

-0.49%

93.80

United Therapeutics Corp.

UTHR

-0.13%

542.66

Siga Technologie

SIGA

-0.76%

3.920

Vertex Pharmaceuticals Inc

VRTX

+2.32%

491.34

Moderna

MRNA

+3.61%

69.70

Charles Riv Labs Intl Inc

CRL

+1.43%

215.75

Medpace Holdings

MEDP

+1.37%

527.07

Talphera Inc

TLPH

+0.97%

1.040

ICLR

China Biologic

CBPO

0.00%

119.99

Iqvia Hldgs Inc

IQV

+2.53%

191.14

MOLN

Arcturus Therape

ARCT

-0.87%

6.82

PRA Health

PRAH

0.00%

165.21

Gilead Sciences Inc

GILD

+3.26%

127.88

Incyte Corp

INCY

+0.40%

113.81

Aptevo Therapeutics Inc

APVO

-0.66%

4.550

Biospecifics

BSTC

+0.15%

88.53

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.